Characterization of immune response towards modified Coxsackie B virus-like particle vaccine in a murine model

Abstract Coxsackievirus Bs (CVBs) are common human RNA viruses that belong to the enterovirus genus of Picornaviridae. Most commonly, infections with these manifest mild flu-like symptoms. However, CVBs also known cause severe diseases, including aseptic meningitis, myocarditis, and chronic dilated cardiomyopathy (DCM), encephalitis, pancreatitis, hand-foot-and-mouth disease. In this study, we aimed for a versatile characterization modified CVB virus-like particle vaccine in murine model. The CVB-VLP was produced using baculovirus-insect cell production platform. Purified characterized administered mice via s.c. or i.m. routes, either without an adjuvant. Immunological response included both humoral cellular characterization. Antigen-specific IgG levels neutralizing antibodies sera were measured determine immune response. To characterize immunity, activation markers lymphocytes identified flow cytometry. Additionally, cytokine secretion stimulated splenocytes determined FluoroSpot assay. induced high vaccinated mice. Further, vitro stimulation mainly CD4+ T-cells, adjuvanted significant level IFN-γ IL-2. These results indicate combined adjuvant is promising candidate. addition, our current challenge study coxsackie B1 virus will shed us more insight on protective role vaccine. Supported by grants from Finnish Foundations (Instrumentarium Science Foundation, Paulo Foundation Ida Montini Foundation)